Literature DB >> 1328936

Pseudo-Bartter's syndrome from surreptitious diuretic intake: differential diagnosis with true Bartter's syndrome.

G Colussi1, G Rombolà, C Airaghi, M E De Ferrari, L Minetti.   

Abstract

Five patients with pseudo-Bartter's syndrome from surreptitious diuretic abuse were compared with six patients with true Bartter's syndrome, diagnosed as a normotensive, hyperreninaemic, hypokalaemic metabolic alkalosis with normal urine chloride excretion, low CH2O/(CH2O+CCl) ratio during maximal water diuresis and negative urine screen for diuretics. The latter was positive for frusemide in four and for hydrochlorothiazide in the remaining pseudo-Bartter's patients. The two groups of patients did not differ as for plasma Na+, Cl-, K+, HCO3-, renin, and aldosterone, while uric acid and Mg2+ were greater in pseudo-Bartter's patients. Daily and fasting urine Na+, Cl- and K+ excretion were less in pseudo-Bartter's patients; however, there was substantial overlap of values between the two groups. Fractional distal solute reabsorption during maximal water diuresis was low in the six patients with Bartter's syndrome and in two pseudo-Bartter's patients; thus, this parameter could not be taken as a specific diagnostic marker of Bartter's syndrome. Frusemide administration, 40 mg i.v., induced a brisk increase of urine flow (11.7-21.8 ml/min), UOsm (148-186 mOsm/kg H2O) and FENa (14.6-24%) in Bartter's syndrome, but not pseudo-Bartter's patients; in all pseudo-Bartter's patients frusemide-induced changes of UOsm (13-97) and FENa (-0.5 to 10.2) were markedly less than in Bartter's syndrome patients. Frusemide resistance in pseudo-Bartter's patients was most probably related to diuretic-induced ECF volume contraction and increased proximal tubule solute reabsorption; in fact fractional lithium clearance (FELi, a marker of post-proximal solute delivery) was low in pseudo-Bartter's, but not in Bartter's syndrome patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328936     DOI: 10.1093/ndt/7.9.896

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  8 in total

Review 1.  Threading through the mizmaze of Bartter syndrome.

Authors:  Willem Proesmans
Journal:  Pediatr Nephrol       Date:  2006-05-16       Impact factor: 3.714

2.  Concealed administration of frusemide simulating Bartter syndrome in a 4.5-year-old boy.

Authors:  M D'Avanzo; R Santinelli; C Tolone; A Bettinelli; M G Bianchetti
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

3.  Autopsy report on pseudo-Bartter syndrome with renal calcification induced by diuretics and diet pills.

Authors:  Kana Unuma; Akihiro Tojo; Kazuki Harada; Kanju Saka; Makoto Nakajima; Takeshi Ishii; Toshiro Fujita; Ken-Ichi Yoshida
Journal:  BMJ Case Rep       Date:  2009-05-25

4.  Furosemide-induced tubular dysfunction responding to prostaglandin synthesis inhibitor therapy in a child with nephrotic syndrome.

Authors:  T Harish Varma; Ashish Sharma; S Santhiya; Lesa Dawman; Karalanglin Tiewsoh
Journal:  CEN Case Rep       Date:  2018-03-22

5.  Furosemide-induced severe hypokalemia with rhabdomyolysis without cardiac arrest.

Authors:  Wolfgang Ruisz; Claudia Stöllberger; Josef Finsterer; Franz Weidinger
Journal:  BMC Womens Health       Date:  2013-07-09       Impact factor: 2.809

6.  An Adult Case of Bartter Syndrome Type III Presenting with Proteinuria.

Authors:  Eun Jung Cha; Won Min Hwang; Sung-Ro Yun; Moon Hyang Park
Journal:  J Pathol Transl Med       Date:  2016-01-11

Review 7.  Bartter syndrome: causes, diagnosis, and treatment.

Authors:  Tamara da Silva Cunha; Ita Pfeferman Heilberg
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-11-09

8.  Severe metabolic alkalosis due to diuretic treatment in a patient with distal renal tubular acidosis: a rare association.

Authors:  Laura Lucaccioni; Elena Coccolini; Alessandra Dozza; Sante Lucio Cantatore; Alberto Berardi; Barbara Predieri; Lorenzo Iughetti
Journal:  Acta Biomed       Date:  2019-05-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.